Eterna Therapeutics Announces Leadership Changes & Compensation Arrangements

TL;DR

**Eterna Therapeutics just shook up its leadership and compensation, signaling potential strategic shifts.**

AI Summary

Eterna Therapeutics Inc. reported on February 12, 2024, the departure of directors or certain officers and the election or appointment of others, along with compensatory arrangements for certain officers. The filing, under SEC File Number 001-11460, indicates changes in leadership and executive compensation, which are key events for the company incorporated in Delaware.

Why It Matters

Changes in executive leadership and compensation can significantly impact a company's strategic direction, operational efficiency, and investor confidence.

Risk Assessment

Risk Level: medium — Changes in leadership can introduce uncertainty but also new opportunities, making it a medium risk event.

Key Numbers

• 001-11460 — SEC File Number (Identifies the specific filing with the SEC)
• 2024-02-12 — Event Date (Date of earliest event reported in the 8-K)

Key Players & Entities

• Eterna Therapeutics Inc. (company) — Registrant
• Delaware (company) — State of Incorporation
• February 12, 2024 (date) — Date of earliest event reported
• 001-11460 (dollar_amount) — Commission File Number
• Cambridge, MA (company) — Principal Executive Offices location

FAQ

Key Financial Figures

• $0.005 — ich registered Common Stock, par value $0.005 per share ERNA The Nasdaq Stock Mar

Filing Documents

• ef20021627_8k.htm (8-K) — 26KB
• 0001140361-24-008273.txt ( ) — 159KB
• erna-20240212.xsd (EX-101.SCH) — 4KB
• erna-20240212_lab.xml (EX-101.LAB) — 22KB
• erna-20240212_pre.xml (EX-101.PRE) — 16KB
• ef20021627_8k_htm.xml (XML) — 4KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 12, 2024, and effective as of that date, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the "Board") of Eterna Therapeutics Inc. (the "Company") appointed Mr. Peter Cicala to the Board. Mr. Cicala will serve as a member of the Board until the Company's 2024 Annual Meeting of Stockholders and until his successor is duly elected or appointed and qualified or his earlier death, resignation or removal. The Board determined that Mr. Cicala is as an "independent director" under applicable rules of the Nasdaq Stock Market. The Board also appointed Mr. Cicala to serve on each of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee of the Board. There are no arrangements or understandings between Mr. Cicala and any other person pursuant to which Mr. Cicala was appointed as a member of the Board. The Company has not engaged in any transaction, and there is no currently proposed transaction, in which Mr. Cicala had or will have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K. Mr. Cicala will participate in the standard non-employee director compensation arrangements with respect to annual Board member compensation and Board committee member retainers described under the heading "Director Compensation" in the Company's Definitive Proxy Statement on Schedule 14A filed with Securities and Exchange Commission on May 5, 2023. The Company also expects to enter into its standard director and officer indemnification agreement with Mr. Cicala. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Ete

View Full Filing

View this 8-K filing on SEC EDGAR